Literature DB >> 11100882

Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas.

S Poppema1, A van den Berg.   

Abstract

Recent studies provide evidence that Reed-Sternberg (R-S) cells produce factors that may explain the characteristic inflammatory infiltrate in the affected tissues of Hodgkin lymphoma. The various chemokines and cytokines that are produced lead to a preferential influx of Th2-type T cells and suppress Th1-type immune responses. Overall, the immunophenotype of the lymphocytes surrounding the R-S cells is consistent with anergic and/or Th2-type T cells. Therefore, these cells do not support a cytotoxic anti-tumor response. Since the R-S cells are neoplastic B cells, the cytokines produced by these T cells may in fact help their growth and/or survival. The production and induction of various other cytokines may also explain the influx of eosinophils (IL-5, eotaxin) and plasma cells (IL-6). Differences in chemokine and cytokine production may be responsible for the differences between the histological subtypes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11100882     DOI: 10.1006/scbi.2000.0327

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  21 in total

Review 1.  Adoptive immunotherapy for Hodgkin's lymphoma.

Authors:  Alana A Kennedy-Nasser; Catherine M Bollard; Cliona M Rooney
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

2.  Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments.

Authors:  Cigdem Atayar; Anke van den Berg; Tjasso Blokzijl; Marcel Boot; Randy D Gascoyne; Lydia Visser; Sibrand Poppema
Journal:  J Clin Pathol       Date:  2006-12-08       Impact factor: 3.411

Review 3.  Immunotherapies for Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard F Ambinder
Journal:  Crit Rev Oncol Hematol       Date:  2007-11-19       Impact factor: 6.312

4.  Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Authors:  Lynn I Levin; Elizabeth C Breen; Brenda M Birmann; Julie L Batista; Larry I Magpantay; Yuanzhang Li; Richard F Ambinder; Nancy E Mueller; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-24       Impact factor: 4.254

5.  Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

Authors:  Jitakshi De; Robert E Brown
Journal:  Int J Clin Exp Med       Date:  2010-01-30

6.  Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.

Authors:  Wouter J Plattel; Anke van den Berg; Lydia Visser; Anne-Marijn van der Graaf; Jan Pruim; Hans Vos; Bouke Hepkema; Arjan Diepstra; Gustaaf W van Imhoff
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 7.  Relationship between Hodgkin's and non-Hodgkin's lymphomas.

Authors:  Rose-Marie Amini; Gunilla Enblad
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

8.  Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.

Authors:  Robert J Biggar; Julia S Johansen; Karin Ekström Smedby; Klaus Rostgaard; Ellen T Chang; Hans-Olov Adami; Bengt Glimelius; Daniel Molin; Stephen Hamilton-Dutoit; Mads Melbye; Henrik Hjalgrim
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

9.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

10.  Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.

Authors:  A Birgersdotter; K R N Baumforth; A Porwit; J Sjöberg; W Wei; M Björkholm; P G Murray; I Ernberg
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.